We are live on ! Find out more
IGC icon

IGC Pharma
IGC

4 hedge funds and large institutions have $318K invested in IGC Pharma in 2013 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

20% less funds holding

Funds holding: 5 → 4 (-1)

41% less capital invested

Capital invested by funds: $535K → $318K (-$217K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
4
Holders Change
-1
Holders Change %
-20%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
U
UBS
Switzerland
+$682

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$35K
2
TRCT
Tower Research Capital (TRC)
New York
-$272
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
1
Wells Fargo
California
$308K – – –
Creative Planning
2
Creative Planning
Kansas
$9K – – –
U
3
UBS
Switzerland
$1K +$682 +547 New
Morgan Stanley
4
Morgan Stanley
New York
– -$35K -22,294 Closed
TRCT
5
Tower Research Capital (TRC)
New York
– -$272 -218 -97%

IGC Hedge Fund Activity: Q3 2013 in Review

4 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q3 2013, worth a combined $318K — down 41% from $535K a quarter earlier.

Fund positioning in IGC was balanced in Q3 2013: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.

The largest buyer was UBS, opening a new position worth an estimated $682. The largest seller was Morgan Stanley, exiting entirely with an estimated $35K sold.

  • 4 institutional investors held IGC Pharma (IGC) as of Q3 2013, down from 5 in Q2 2013.
  • Funds reported $318K of IGC Pharma stock for Q3 2013, down 41% quarter-over-quarter.
  • 1 fund opened new IGC Pharma positions in Q3 2013 and 1 closed out, a net change of 0 holders.
  • The largest IGC Pharma buyer in Q3 2013 was UBS, an estimated $682 added.
  • The largest IGC Pharma seller in Q3 2013 was Morgan Stanley, an estimated $35K sold.

Based on aggregated 13F filings for Q3 2013.